Sirolimus for unknown-cause retroperitoneal scarring
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests sirolimus to treat idiopathic (unknown-cause) retroperitoneal fibrosis, a condition where scar tissue forms in the belly behind the kidneys. You may be considered if imaging and blood tests suggest active inflammation, and if you’re able to safely take the study medicine and return for follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your scan (CT or MRI) suggests idiopathic retroperitoneal fibrosis (unknown cause)
- If the cause seems uncertain or unusual, you must have a biopsy to confirm it is idiopathic
- Your blood tests show inflammation from this condition (higher ESR and/or CRP) and/or active lesions on imaging
- Your fibrosis is NOT due to something else (it must be idiopathic, not secondary)
- You must not have taken steroid, immune-suppressing, or biologic medicines in the last 3 months
- You must be able to safely take prednisone or sirolimus (no allergy/contraindication) and be able to follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests sirolimus, an immune-system-calming medicine, for people with lupus who also have very low platelet counts (ITP). It may help reduce bleeding risk and improve platelet numbers.
This trial studies sirolimus in adults with “warm” autoimmune hemolytic anemia (or Evans syndrome) when steroids have not worked or the anemia has returned. It may help control the immune attack on red blood cells, but there are specific safety checks for liver health and infections.
This trial tests if the drug sirolimus can help people with focal seizures (starting in one part of the brain) that don't improve with at least two other medications. It aims to reduce seizure frequency in adults aged 18 to 60.
This trial tests if sirolimus (an immune-suppressing drug) works better than current treatments for aplastic anemia patients who did not improve or had side effects from cyclosporin. It aims to find a new option to help your body make more blood cells.
This Phase 2 trial tests sirolimus (a medicine that affects the immune system) to reduce symptoms and disease activity in adults with active systemic lupus erythematosus (SLE). You may be a good fit if your lupus is currently active despite stable standard treatments.
This Phase 2 trial studies whether sirolimus can slow or prevent functional decline (more difficulty with daily activities) in older adults. You may be considered if you’re in the right age range and have no major heart, lung, liver, kidney, or recent bleeding/clotting problems.
Hear when a new Retroperitoneal Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.